FR2766705B1 - Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation - Google Patents

Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation

Info

Publication number
FR2766705B1
FR2766705B1 FR9709698A FR9709698A FR2766705B1 FR 2766705 B1 FR2766705 B1 FR 2766705B1 FR 9709698 A FR9709698 A FR 9709698A FR 9709698 A FR9709698 A FR 9709698A FR 2766705 B1 FR2766705 B1 FR 2766705B1
Authority
FR
France
Prior art keywords
neutral
cationic
preparation
biologically active
particle complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9709698A
Other languages
English (en)
Other versions
FR2766705A1 (fr
Inventor
Alain Thierry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovector Therapeutics SA
Original Assignee
Biovector Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovector Therapeutics SA filed Critical Biovector Therapeutics SA
Priority to FR9709698A priority Critical patent/FR2766705B1/fr
Priority to FR9710812A priority patent/FR2766706B1/fr
Priority to DE69826488T priority patent/DE69826488T2/de
Priority to PCT/EP1998/005103 priority patent/WO1999006026A1/fr
Priority to JP2000504841A priority patent/JP2001511440A/ja
Priority to AT98945216T priority patent/ATE276742T1/de
Priority to CA002296394A priority patent/CA2296394A1/fr
Priority to EP98945216A priority patent/EP1001750B1/fr
Priority to US09/126,402 priority patent/US6096335A/en
Priority to ES98945216T priority patent/ES2229534T3/es
Priority to AU92608/98A priority patent/AU9260898A/en
Publication of FR2766705A1 publication Critical patent/FR2766705A1/fr
Application granted granted Critical
Publication of FR2766705B1 publication Critical patent/FR2766705B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9709698A 1997-07-30 1997-07-30 Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation Expired - Fee Related FR2766705B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR9709698A FR2766705B1 (fr) 1997-07-30 1997-07-30 Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation
FR9710812A FR2766706B1 (fr) 1997-07-30 1997-08-29 Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
ES98945216T ES2229534T3 (es) 1997-07-30 1998-07-30 Complejos en forma de particulas estables, con carga global neutra o negativa de estructura laminar.
JP2000504841A JP2001511440A (ja) 1997-07-30 1998-07-30 層状構造の、中性あるいは陰性グローバル電荷を持つ安定粒状複合体
AT98945216T ATE276742T1 (de) 1997-07-30 1998-07-30 Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung
CA002296394A CA2296394A1 (fr) 1997-07-30 1998-07-30 Complexes particulaires stables de charge globale neutre ou negative, de structure lamellaire
DE69826488T DE69826488T2 (de) 1997-07-30 1998-07-30 Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung
US09/126,402 US6096335A (en) 1997-07-30 1998-07-30 Stable particulate complexes having a lamellar, rolled, and condensed structure
PCT/EP1998/005103 WO1999006026A1 (fr) 1997-07-30 1998-07-30 Complexes particulaires stables de charge globale neutre ou negative, de structure lamellaire
AU92608/98A AU9260898A (en) 1997-07-30 1998-07-30 Stable particulate complexes with neutral or negative global charge of lamellar structure
EP98945216A EP1001750B1 (fr) 1997-07-30 1998-07-30 Complexes particulaires stables de charge globale neutre ou negative, de structure lamellaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9709698A FR2766705B1 (fr) 1997-07-30 1997-07-30 Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation

Publications (2)

Publication Number Publication Date
FR2766705A1 FR2766705A1 (fr) 1999-02-05
FR2766705B1 true FR2766705B1 (fr) 2001-05-25

Family

ID=9509805

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9709698A Expired - Fee Related FR2766705B1 (fr) 1997-07-30 1997-07-30 Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation

Country Status (1)

Country Link
FR (1) FR2766705B1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
WO1991017424A1 (fr) * 1990-05-03 1991-11-14 Vical, Inc. Acheminement intracellulaire de substances biologiquement actives effectue a l'aide de complexes de lipides s'auto-assemblant
AU6691496A (en) * 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
DE19605548A1 (de) * 1996-02-15 1997-09-04 Boehringer Ingelheim Int Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
FR2751222B1 (fr) * 1996-07-16 1998-10-09 Capsulis Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique

Also Published As

Publication number Publication date
FR2766705A1 (fr) 1999-02-05

Similar Documents

Publication Publication Date Title
PT1003478E (pt) Preparacoes aquosas de aerossol contendo macromoleculas biologicamente activas e processo para a preparacao dos respectivos aerossois
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
FR2761889B1 (fr) Patch pharmaceutique, cosmetique ou dermo-pharmaceutique pour la delivrance de plusieurs composes actifs de nature differente
FR2714382B1 (fr) Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
FR2733684B1 (fr) Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
FR2740333B1 (fr) Utilisation d'un antagoniste de substance p dans une composition topique comme agent antitranspirant
FR2737408B1 (fr) Utilisation d'un antagoniste de bradykinine dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
AU9260898A (en) Stable particulate complexes with neutral or negative global charge of lamellar structure
MA26434A1 (fr) Composes n-alkylfuranne-nitrone et leur utilisation en tant q'agents pharmaceutiques
FR2766705B1 (fr) Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation
ID24222A (id) TURUNAN-TURUNAN 3-TERSUBSTITUSI 3,4,5,7-TETRAHIDROPIROLO [3',4':4,5] TIENO- [2,3-d] PIRIMIDIN, PEMBUATAN DAN PENGGUNAANNYA
FR2761363B1 (fr) Polypeptide purifie de l'epiderme et son utilisation
MC2274A1 (fr) Formes d'application solides pour la voie orale qui contiennent de l'ifosfamide comme substance active
FR2761074B1 (fr) Composes a base de silicium biologiquement actifs sous forme solide
FR2723317B1 (fr) Utilisation d'antagonistes de la neurotensine pour la preparation de medicaments diuretiques
DE69722623D1 (de) Verabreichungssystem von funktionellen wirkstoffen
MD283F1 (ro) Compozitie de ingrediente pentru balsamul tonifiant "legenda"
FR2761064B1 (fr) Piperazines derivees d'amines cycliques, leur preparation et leur application comme medicaments
ZA984970B (en) Processes for preparation of Marek's disease virus using continuous mammalian cell lines.
FR2762526B1 (fr) Malaxeur d'alginate ameliore
DE19882184T1 (de) Cyclosporin enthaltende Präparation
FR2727864B1 (fr) Utilisation des ligands des sites de liaison peripherique pour les benzodiazepines pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques
FR2753095B1 (fr) Utilisation de la melatonine comme agent anti-inflammatoire dans une composition cosmetique ou pharmaceutique
FR2759584B1 (fr) Composition pharmaceutique pour l'administration orale de composes heterocycliques sous forme ammonium quaternaire

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080331